Conclusion
From a global perspective, the safe application of therapeutic
strategies to COVID-19 can only be effectively achieved by drug
repurposing. In this regard,
tetracyclines combine potentially beneficial direct anti-viral activity
with anti-inflammatory and immunomodulatory properies, as well as
anti-bacterial effect, that can together assist in the therapeutic
management of severe cases of COVID-19. Their confirmed benefit in the
treatment of ARDS strongly supports the notion that they would be of
interest for the treatment COVID-19. In addition, Tetracyclines are
safe, well-knownand economically accessible, with doxycycline among the
WHO essential medicines. This positions them as excellent therapeutic
candidates for the management of COVID-19, particularly in developing
countries where successful vaccination programs have yet to be
established and access to other therapeutic resources is scarce.